by Peter Breggin MD & Ginger Breggin, America Outloud:
She had a sparkling British accent and spoke crisply. Her responses to me were sprinkled with “brilliant” and “lovely.” She told me, “Now that first proof of concept”1 has been established, the next wave of mRNA products is coming down the pipeline with over $50 billion market share this year.2 She is a representative of Hanson Wade, a company producing the 3rd Annual mRNA-Based Therapeutics Summit (“Supercharging the Next Wave of efficacious mRNA Therapeutics & Vaccines). Her job is “curating the audience for the upcoming 3rd mRNA-Based Therapeutics Summit this July.” She was calling me because I requested information about the summit and provided my contact details as requested.
